Media Coverage

Dr Marshall for OncLive

FDA Approval of Fruquintinib Expands Later-Line Treatment Options in mCRC

December 5th, 2023

John L. Marshall, MD, sheds light on the significance of the FDA approval of fruquintinib for patients with heavily pretreated metastatic colorectal cancer and discusses the efficacy and safety data from the FRESCO and FRESCO-2 trials that supported the decision in this population.…